Arvinas raises $19.25m for novel protein degradation approach
This article was originally published in Scrip
Arvinas raised $19.25m in a Series A venture funding round and from the state of Connecticut to finance drug candidates that degrade disease-causing proteins, rather than inhibit them, and address targets that have eluded drug developers in the past.
You may also be interested in...
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
Oncology R&D head Axel Hoos spoke with Scrip about data at ASCO and the company’s strategy in immuno-oncology, cancer epigenetics, cell and gene therapy and synthetic lethality.
Private Company Edition: Arvelle, insitro, AbCellera and the University of Michigan have something in common – they each attracted more than $100m in venture capital investment.